2) It directly kills cancer cells.
3) It signals the immune system to mount an effective and sustainable
anti-tumor immune response by changing the type of cells that
infiltrate and attack the tumor from the 'usual' CD-8 cells to the
CD-4 cells. This is important because:
-- The tumor is able to shut down the infiltrating CD-8 cells,
but is unable to shut down the CD-4 cell attack, and
-- CD-4 cells help break 'tumor tolerance', thereby allowing
the immune system to recognize, attack, and destroy the
tumor. (The normal immune system is 'blind' to tumor cells
because the tumor cells are derived from the body's own
cells, and thus the body 'thinks' of the tumor as 'self', a
phenomenon also known as 'tumor tolerance'.)
4) Multikine has been shown to render the remaining cancer cells much
more susceptible to radiation and chemotherapy treatment, thereby
making these treatments more effective.
Our U.S. and Canadian cleared Phase III clinical trial is designed to prove that Multikine is effective in the treatment of advanced primary head and neck cancer patients. This disease is being developed as Multikine's first indication because it is a fatal disease with an unmet medical need. Over the past 50 years there has been very little improvement in the survival of these patients (about 50% after 3 years).
However, because Multikine simulates a healthy immune response, it is
also expected to be effective in treating many other tumors. Multikine will
be developed for use in treating breast cancer, skin cancer and cervical
cancer. Studies will also be conducted to confirm observations made during
Phase II clinical studies that Multikine has the ability to increase the
effectiveness of radiation and chemotherapy. This may someday lead to an
ability to reduce the amounts of
|SOURCE CEL-SCI Corporation|
Copyright©2007 PR Newswire.
All rights reserved